Karyopharm Therapeutics Inc. — Form 8-K
Filed November 2, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 95/100
What the filing says
Karyopharm Therapeutics Inc. (market cap ~$37M) has filed voluntary Chapter 11 bankruptcy petitions and entered a Restructuring Support Agreement with Ayrmid Ltd. as the lead bidder in a court-supervised sale process. Karyopharm secured $55 million in debtor-in-possession financing from existing secured lenders to fund operations during bankruptcy. The transaction is expected to close in Q1 2027, with Ayrmid acquiring Karyopharm's assets including marketed products (XPOVIO for multiple myeloma and myelofibrosis) and pipeline. The company will continue ordinary course operations and pursue bidding procedures to maximize stakeholder value.
Why this rating
Bankruptcy restructuring is existential for a $37M market-cap biotech. Equity likely wiped out; DIP financing and sale process indicate financial distress but continuity. Transformational event for the company's independence and shareholders.
Tradability signal
NO TRADE
No trade: price $0.14 is below our $0.5 floor — spreads at this level eat any edge. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it negative)
before filing · preread $0.21 ▲ 40.00% | at our read · unknown $0.15 | +10 min · unknown $0.11 ▼ 27.33% | +30 min · unknown $0.10 ▼ 35.33% | +1 hr pending | +4 hrs pending |
The stock had already moved -28.57% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 2, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.